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ABSTRACT
Objectives: To investigate the associations of
objectively measured moderate-to-vigorous-intensity
physical activity (MVPA) and body mass index (BMI)
with glycated haemoglobin (HbA1c) in a national
sample of English adults.
Methods: The 2008 Health Survey for England data
were used with 1109 participants aged ≥18 providing
complete data. MVPA time was assessed using an
accelerometer. Weighted linear regression models,
adjusted for several confounders, quantified the
associations between continuous measures of MVPA
and BMI with HbA1c. Interaction analyses were
implemented to observe whether the association of
MVPA with HbA1c was modified by BMI or vice versa.
Further weighted linear regression models examined
the differences in HbA1c across four mutually exclusive
categories of MVPA and BMI: (1) ‘physically active and
non-obese’, (2) ‘physically active and obese’, (3)
‘physically inactive and non-obese’ and (4) ‘physically
inactive and obese’. ‘Physically active’ was defined as:
≥150 min/week of MVPA. ‘Obese’ was defined as: BMI
≥30.0 kg/m2. A wide range of sensitivity analyses were
also implemented.
Results: Every 30 min/day increment in MVPA was
associated with a 0.7 mmol/mol (0.07% (p<0.001))
lower HbA1c level. Each 1 kg/m2 increment in BMI was
associated with a 0.2 mmol/mol (0.02% (p<0.001))
higher HbA1c level. The association of MVPA with
HbA1c was stronger in obese individuals (−1.5 mmol/
mol (−0.13% (p<0.001))) than non-obese individuals
(−0.7 mmol/mol (−0.06% (p<0.001))); p=0.004 for
interaction. The association of BMI with HbA1c
remained stable across MVPA categories. Compared
with individuals categorised as ‘physically inactive and
obese’, only those categorised as ‘physically active and
obese’ or ‘physically active and non-obese’ had lower
HbA1c levels by 2.1 mmol/mol (0.19% (p=0.005)) and
3.5 mmol/mol (0.32% (p<0.001)), respectively.
Sensitivity analyses indicated robustness and stability.
Conclusions: This study emphasises the importance
of physical activity as a determinant of HbA1c, and
suggests that the associations may be stronger in
obese adults.
INTRODUCTION
Diabetes mellitus is one of the most preva-
lent and costly chronic conditions account-
ing for between 7% and 14% of healthcare
funding globally.1 This healthcare burden is
projected to continue rising into the future.2
Type 2 diabetes mellitus (T2DM), the most
common form of the condition, is conse-
quently recognised as a healthcare priority.
Given T2DM is predominantly a lifestyle-
related chronic condition and that lifestyle
interventions have consistently been shown
to reduce the risk of T2DM across a range of
diverse populations,3 prevention strategies
Strengths and limitations of this study
▪ This study uses glycated haemoglobin (HbA1c)
as an outcome, a validated and clinically
employed measure of diabetes risk.
▪ An objective measure of physical activity is
employed.
▪ The cross-sectional design eliminates the possi-
bility of establishing causality.
▪ The sample used in this study may not be com-
pletely representative of the general population.
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are largely focused on the promotion of healthy beha-
viours. In England, the National Health Service (NHS)
has recently identified the prevention of T2DM as a
leading priority and commissioned a national diabetes
prevention programme based on behavioural counsel-
ling and lifestyle interventions that promote physical
activity and weight loss in those at high risk.4
Revisions to the diagnostic criteria for T2DM in 2011
to include glycated haemoglobin (HbA1c),5 an easy to
assess and increasingly used measure of glycaemia that
reflects average glucose concentrations over the previ-
ous 2–3 months, precipitated clinical changes more
widely in the assessment of metabolic health.4–6
However, while the effects of physical activity and weight
loss on HbA1c are well defined in populations with
T2DM,7–9 they are less clear in populations without
diabetes.10
In this study, we use data from a national survey to
quantify the associations of objectively measured
moderate-to-vigorous-intensity physical activity (MVPA)
and body mass index (BMI) with HbA1c in the general
population, and observe whether the association of
MVPA with HbA1c is modified by BMI or vice versa.
Here, we hypothesise that MVPA may provide a metabol-
ically protective effect in obese individuals; since cardio-
respiratory fitness, a factor that is partly moderated by
MVPA, has previously been shown to be an important
determinant of metabolic health in obesity.11 We also
examine the differences in HbA1c across mutually exclu-
sive categories of MVPA and BMI.
METHODS
Study sample
The Health Survey for England (HSE) is a series of
national annual surveys designed to examine the
health and well-being of people living in England.12 13
To obtain a population-based sample, these cross-
sectional surveys employ a multistage stratified random
sampling procedure. The 2008 HSE wave was centred
on physical activity and fitness and included a subset
of participants who were randomly selected to wear an
accelerometer for the objective assessment of physical
activity.12 13 In total, accelerometer data on 2313 adults
(aged ≥ 18) were available, with 2131 adults providing
valid accelerometer data (see online supplementary
materials figure S1). Participants provided written
informed consent. Further details are reported
elsewhere.12 13
Physical activity
Physical activity and sedentary time were measured
using an ActiGraph GT1M accelerometer (ActiGraph
Corporation, Pensacola, Florida, USA) which was worn
on the right hip for seven consecutive days during
waking hours (except water-based activities).12 The
ActiGraph GT1M device was initialised to collect data
using 1 min epochs. Accelerometer files were processed
using KineSoft V3.3.76 (KineSoft, Loughborough, UK).
Accelerometer counts were used to calculate the total
time spent in MVPA (≥1952 counts/min), light-
intensity physical activity (≥100 to <1952 counts/min)
and sedentary behaviour (<100 counts/min).14 15
Non-wear-time was defined as any periods of continu-
ous zero counts for ≥60 consecutive minutes.16 Valid
accelerometry data were defined as ≥10 hours of wear-
time per day with ≥4 days of data. The average number
of minutes per valid day spent in each intensity band
were calculated.
While time in total accumulated MVPA was used for
the primary analysis, MVPA time accumulated in bouts
of ≥10 min (allowing for a 2 min exception in the inten-
sity threshold) was also derived for a sensitivity analysis
(see Statistical analysis—Sensitivity analysis).
Body mass index (BMI)
A trained fieldworker recorded height (measured to the
nearest 0.1 cm) and weight (measured to the nearest
0.1 kg using an electronic scale) readings.13 BMI was cal-
culated as the weight (in kilograms) divided by the
square of the height (in metres).
Waist circumference
Waist circumference was defined as the midpoint
between the lower rib and the upper boundary of the
iliac crest. A nurse measured this twice to the nearest
0.1 cm using a tape and the average of the two readings
was used.13 This variable was included as differences in
lean mass may exaggerate findings for physically active
and obese individuals under the BMI measure.
Therefore, sensitivity analyses replacing BMI with waist
circumference were executed (see Statistical analysis—
Sensitivity analysis).
Glycated haemoglobin (Hba1c)
Non-fasting blood samples were collected by a nurse for
the analysis of HbA1c.13 Blood analytes were assayed at
the Royal Victoria Infirmary laboratory in Newcastle
upon Tyne, England. Further details are reported else-
where.12 13 Data on HbA1c are reported in dual units:
mmol/mol (to one decimal place) and % (to two
decimal places).
Covariates
The following factors, collected by a trained fieldworker,
were also used: age (in years); disease index (no
diseases, one or more diseases); ethnicity (white,
non-white); reported fruit and vegetable consumption
(0, 1–3, 4–6, 7+ portions/day); income (low, intermedi-
ate, high); sex (men, women); smoking status (never
smoked, ex-smoker, current smoker); socioeconomic
status (national statistics socioeconomic classification:
high, high-intermediate, intermediate, low-intermediate,
low); and any prescribed medication (no, yes). The
‘disease index’ variable was based on physician diag-
nosed conditions/illnesses relating to the following
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systems: blood and related organs; digestive; ear; endo-
crine and metabolic; eye; genitourinary; heart and circu-
latory; infectious and parasitic; mental disorders;
musculoskeletal; neoplastic; nervous; respiratory; skin;
and any other structure. Further details are reported
elsewhere.12 13
Statistical analysis
All statistical analyses were conducted using Stata/IC
V14.0 (Stata Corporation, College Station, Texas, USA)
and controlled for the complex survey strategy employed
in the 2008 HSE (primary sampling units, clustering
and survey weights) to produce estimates representing
the national population.12 13
Covariate selection and missing data
Multiple linear regression models were used to assess
the associations between measures of total accumulated
MVPA time and BMI with HbA1c after the adjustment
for confounders. Confounders were considered for
inclusion as follows: primarily using all the available
data, in separate models for MVPA and BMI with HbA1c
as the dependent variable, confounders were included
based on the criteria of changing the regression coeffi-
cient for either MVPA or BMI by 10% or more once
added individually to a basic model adjusted for age,
ethnicity, sex and accelerometer wear-time.17 The con-
founders examined included: income, socioeconomic
status, disease index, any prescribed medication,
smoking status, reported fruit and vegetable consump-
tion, light-intensity physical activity time and sedentary
time. Of these, only income and any prescribed medica-
tion affected the relationships of MVPA and BMI with
HbA1c (see online supplementary materials table S1),
and were therefore included as confounders in all ana-
lyses. A complete case analysis was used for handling any
missing data (BMI (n=185), HbA1c (n=746) and covari-
ate: income (n=334)). In total, 1109 adults provided
valid accelerometer data with complete BMI, HbA1c and
covariate (age, ethnicity, income, sex, any prescribed
medication and accelerometer wear-time) data and were
included for analysis (see online supplementary
materials figure S1). Participant characteristics of the
included sample (n=1109) were tabulated. Categorical
variables were presented as numbers and proportions,
whereas continuous variables were summarised as means
and SDs. As a supplementary analysis, we compared the
basic characteristics (age, BMI, waist circumference, eth-
nicity, sex, total MVPA time and MVPA time accumu-
lated in bouts of ≥10 min) between the included and
excluded participants from the sample of adults who
provided valid accelerometer data; both groups were
similar (see online supplementary materials table S2).
Continuous measures of MVPA and BMI
Model 1 examined the associations between continuous
measures of total accumulated MVPA time (presented
as 30 min/day increments) or BMI (presented as of
1 kg/m2 increments) with HbA1c, and adjusted for: age,
ethnicity, income, sex, any prescribed medication and
accelerometer wear-time. Model 2 further adjusted for
BMI (for MVPA analysis) and MVPA (for BMI analysis).
Interaction analyses investigated if results for MVPA and
BMI were modified by sex (significant results, if any,
were stratified by men and women) and age (significant
results, if any, were stratified at 60 years of age), and
whether the association of MVPA with HbA1c was modi-
fied by BMI or vice versa (significant results, if any, were
stratified at 150 min/week of MVPA; and at a BMI
threshold of 30.0 kg/m2).
Mutually exclusive categories of MVPA and BMI
For descriptive purposes and to investigate the separate
and combined associations of physical activity and
obesity, a multiple linear regression model was fitted to
analyse the differences in HbA1c between mutually
exclusive categories of total accumulated MVPA time
and BMI. To mirror national and international guid-
ance,18 19 MVPA status was classified as ‘physically active’
or ‘physically inactive’ on the basis of whether or not
participants accumulated a total of ≥150 min/week of
MVPA, respectively. BMI status was determined as ‘non-
obese’ or ‘obese’ on the basis of a BMI threshold of
30.0 kg/m2 (ie, non-obese if BMI<30.0 kg/m2 and obese
if BMI≥30.0 kg/m2). These categories allowed four
mutually exclusive groups: (1) ‘physically active and non-
obese’, (2) ‘physically active and obese’, (3) ‘physically
inactive and non-obese’ and (4) ‘physically inactive and
obese’. The weighted prevalence (n (%)) and character-
istics of the participants in each category were computed
and tabulated. The ‘physically inactive and obese’ cat-
egory was selected as the reference group as it was
hypothesised a priori to be the least desirable state. The
model adjusted for all the covariates stated previously
(ie, age, ethnicity, income, sex, any prescribed medica-
tion and accelerometer wear-time).
All reported p values were two sided, and to account
for multiple comparisons, p<0.01 was considered to be
statistically significant for all analyses. Results for the
regression analyses are presented as mean differences
(99% CIs) in HbA1c.
Sensitivity analysis
To examine the robustness of the reported associations,
the following sensitivity analyses were conducted: (1)
BMI was replaced with waist circumference (presented
as 1 cm increments) in all described investigations with
mutually exclusive categorical data defined as ‘obese’
(≥102 cm for men and ≥88 cm for women) or ‘non-
obese’ (<102 cm for men and <88 cm for women); (2)
‘Obese’ was defined as having a BMI of ≥27.5 kg/m2 for
the mutually exclusive categorical data; and (3)
Participants were only classified into the ‘physically
active’ categories if they accumulated ≥150 min/week of
MVPA in bouts of ≥10 min for the mutually exclusive
categorical data.
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RESULTS
Participant characteristics
Table 1 displays the characteristics of the included 1109
participants (mean age (SD)=51.0 (16.5) years; mean
BMI (SD)=27.3 (4.8) kg/m2; mean total accumulated
MVPA time (SD)=30.8 (25.8) minutes) across the
derived mutually exclusive categories of MVPA and BMI.
Continuous measures of MVPA and BMI
Table 2 displays the associations between continuous
measures of total accumulated MVPA time, BMI and
HbA1c. In the maximally adjusted model, every 30 min/
day increment in MVPA was associated with a 0.7 mmol/
mol (0.07% (p<0.001)) lower HbA1c level. Each 1 kg/m2
increment in BMI was associated with a 0.2 mmol/mol
(0.02% (p<0.001)) higher HbA1c level. Results were not
modified by age (p=0.104 for age × MVPA interaction;
p=0.300 for age × BMI interaction) or sex (p=0.975 for
sex × MVPA interaction; p=0.170 for sex × BMI inter-
action). However, the MVPA × BMI interaction term was
significant (p=0.004). Table 3 displays the associations of
MVPA with HbA1c stratified by BMI status, and the asso-
ciations of BMI with HbA1c stratified by MVPA status.
The association of MVPA with HbA1c was stronger in
obese individuals, where every 30 min/day increment in
MVPA was associated with a 1.5 mmol/mol (0.13%
(p<0.001)) lower HbA1c level. In non-obese individuals,
every 30 min/day increment in MVPA was associated with
Table 1 Participant characteristics
Characteristic
Sample
N=1109
‘Physically
active and
non-obese’
n=493; 45.9%
‘Physically
active and
obese’
n=118; 10.7%
‘Physically
inactive and
non-obese’
n=343; 29.9%
‘Physically
inactive and
obese’
n=155; 13.5%
Age (years)* 51.0 (16.5) 46.0 (14.7) 51.1 (13.2) 55.2 (18.4) 58.4 (15.0)
Body mass index (kg/m2)* 27.3 (4.8) 25.1 (2.7) 33.4 (3.0) 25.5 (3.2) 34.3 (3.9)
By sex
Men 27.6 (4.2) 25.4 (2.6) 33.3 (2.5) 26.3 (2.6) 34.2 (3.1)
Women 27.0 (5.4) 24.6 (2.9) 33.5 (3.6) 24.8 (3.4) 34.4 (4.4)
Waist circumference (cm)* 92.9 (13.9) 87.3 (10.5) 106.9 (9.5) 89.6 (12.2) 109.1 (11.3)
By sex
Men 98.4 (12.1) 92.2 (9.0) 112.0 (7.6) 97.6 (9.4) 114.1 (9.0)
Women 87.2 (13.5) 81.1 (8.9) 101.2 (7.9) 83.3 (10.1) 104.8 (11.4)
Ethnicity†
White 1055 (94.2) 470 (94.7) 112 (94.3) 324 (93.4) 149 (94.7)
Non-white 54 (5.8) 23 (5.3) 6 (5.7) 19 (6.6) 6 (5.3)
Income†
Low 287 (24.0) 92 (16.7) 31 (24.3) 111 (30.6) 53 (33.5)
Intermediate 364 (33.5) 159 (32.9) 43 (38.5) 107 (32.0) 55 (35.6)
High 458 (42.5) 242 (50.4) 44 (37.2) 125 (37.4) 47 (30.9)
Sex†
Men 523 (50.2) 257 (55.4) 60 (53.5) 142 (43.5) 64 (45.0)
Women 586 (49.8) 236 (44.6) 58 (46.5) 201 (56.5) 91 (55.0)
Any prescribed medication†
No 503 (47.7) 278 (58.0) 57 (49.3) 129 (40.1) 39 (28.5)
Yes 606 (52.3) 215 (42.0) 61 (50.7) 214 (59.9) 116 (71.5)
Accelerometer wear-time* (number of
minutes/valid day)
867.7 (72.1) 873.2 (68.9) 870.4 (77.1) 854.9 (74.7) 875.1 (69.3)
Total accumulated
moderate-to-vigorous-intensity physical
activity time* (number of minutes/valid day)
30.8 (25.8) 47.2 (25.5) 41.3 (18.6) 11.5 (6.4) 9.7 (5.9)
Moderate-to-vigorous-intensity physical
activity time in bouts of ≥10 min*
(number of minutes/valid day)
10.8 (16.2) 39.8 (22.0) 36.4 (11.7) 5.6 (6.1) 4.5 (5.8)
Number of valid days†
4 46 (4.5) 17 (3.9) 9 (8.0) 12 (3.5) 8 (6.1)
5 80 (7.5) 32 (6.7) 5 (4.3) 31 (9.3) 12 (8.5)
6 209 (19.7) 89 (18.4) 20 (18.0) 77 (24.1) 23 (15.8)
7 774 (68.3) 355 (71.0) 84 (69.7) 223 (63.1) 112 (69.6)
Glycated haemoglobin (HbA1c) (mmol/mol)* 38.1 (7.3) 36.1 (4.9) 38.5 (4.8) 39.2 (9.2) 41.9 (8.7)
(%)* 5.63 (0.67) 5.45 (0.45) 5.67 (0.44) 5.74 (0.84) 5.98 (0.79)
All analyses controlled for primary sampling units, clustering and survey weights.
*Continuous variable; mean (SD).
†Categorical variable; n (proportion (%)).
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a 0.7 mmol/mol (0.06% (p<0.001)) lower HbA1c level.
In contrast, the association of BMI with HbA1c remained
stable across MVPA categories.
Mutually exclusive categories of MVPA and BMI
Table 4 shows the differences in HbA1c levels between
mutually exclusive categories of total accumulated MVPA
time and BMI. Compared with individuals who were
‘physically inactive and obese’, those who were ‘physically
active and obese’ or ‘physically active and non-obese’ had
significantly lower HbA1c levels by 2.1 mmol/mol (0.19%
(p=0.005)) and 3.5 mmol/mol (0.32% (p<0.001)),
respectively. However, average HbA1c levels were not sig-
nificantly different between the ‘physically inactive and
non-obese’ and ‘physically inactive and obese’ categories.
Sensitivity analysis
Sensitivity analyses indicated robustness. When waist cir-
cumference was used in place of BMI, the pattern of
results was unchanged (see online supplementary
materials table S3). The results were not modified by
age (p=0.069 for age × MVPA interaction; p=0.922 for
age × waist circumference interaction) or sex (p=0.923
for sex × MVPA interaction; p=0.483 for sex × waist
circumference interaction). However, the pattern of
results was exaggerated for the MVPA × waist circumfer-
ence interaction analysis (p<0.001 for interaction; see
online supplementary materials table S4). In those with
high waist circumference, every 30 min/day increment
in MVPA was associated with a 1.8 mmol/mol (0.16%
(p<0.001)) lower HbA1c level. The other sensitivity ana-
lyses also indicated stability; although the prevalence in
each category varied across the different methods used
(see online supplementary materials table S5), the key
findings were largely unaffected (see online
supplementary materials table S6).
DISCUSSION
This study quantified the independent and combined
associations of objectively measured MVPA and BMI
with HbA1c in a sample of English adults. MVPA and
BMI were independently associated with HbA1c; every
30 min/day increment in MVPA was associated with a
0.7 mmol/mol (0.07%) lower HbA1c level and each
1 kg/m2 increment in BMI was associated with a
0.2 mmol/mol (0.02%) higher HbA1c level. Results for
MVPA were modified by BMI status, with a stronger
Table 2 Adjusted linear regression models showing the associations between continuous measures of total accumulated
moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated haemoglobin (HbA1c)
Adjusted linear
regression model HbA1c (dual units)
MVPA (30 min/day) BMI (1 kg/m2)
Beta (99% CI)* p Value Beta (99% CI)† p Value
Model 1 (mmol/mol)
(%)
−0.9 (−1.4 to −0.4)
−0.08 (−0.13 to −0.04)
<0.001 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
Model 2 (mmol/mol)
(%)
−0.7 (−1.2 to −0.2)
−0.07 (−0.11 to −0.02)
<0.001 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
All analyses controlled for primary sampling units, clustering and survey weights. Bold indicates statistical significance at p<0.01. Model 1
adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer wear-time. Model 2 additionally adjusted for BMI
(for MVPA analysis) and MVPA (for BMI analysis).
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 30 min/day increment in MVPA.
†Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 1 kg/m2 increment in BMI.
Table 3 Interaction analysis: adjusted linear regression models showing the associations between continuous measures of
total accumulated moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated
haemoglobin (HbA1c) stratified by MVPA and BMI levels
p Value of MVPA ×
BMI interaction term Stratification
HbA1c
(dual units)
MVPA (30 min/day) BMI (1 kg/m2)
Beta (99% CI)* p Value Beta (99% CI)† p Value
0.004 BMI<30.0 kg/m2 (mmol/mol)
(%)
−0.7 (−1.2 to −0.1)
−0.06 (−0.11 to −0.01)
0.002 – –
BMI≥30.0 kg/m2 (mmol/mol)
(%)
−1.5 (−2.3 to −0.6)
−0.13 (−0.21 to −0.05)
<0.001 – –
MVPA<150 mins/
week
(mmol/mol)
(%)
– – 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
MVPA≥150 mins/
week
(mmol/mol)
(%)
– – 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
All analyses controlled for primary sampling units, clustering and survey weights. Bold indicates statistical significance at p<0.01.
Models adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer wear-time.
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 30 min/day increment in MVPA.
†Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 1 kg/m2 increment in BMI.
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association seen in obese individuals. For those with a
BMI of 30.0 kg/m2 or higher, every 30 min/day incre-
ment in MVPA was associated with a 1.5 mmol/mol
(0.13%) lower HbA1c level. Compared with individuals
categorised as ‘physically inactive and obese’, only those
categorised as ‘physically active and obese’ or ‘physically
active and non-obese’ had lower HbA1c levels by
2.1 mmol/mol (0.19%) and 3.5 mmol/mol (0.32%),
respectively.
Strengths and limitations
Our study has several strengths, which include: the use
of HbA1c, a validated and clinically employed measure
of glycaemic status; a well-characterised national survey
which employs a multifaceted stratified random sampling
procedure; examining age and sex interactions; and a
range of sensitivity analyses. The key limitation resides in
the cross-sectional design which eliminates the possibility
of establishing causality. In addition, although we
adjusted for a wide range of important lifestyle, demo-
graphic and clinical variables, it is possible that unmeas-
ured factors were confounding the reported associations.
Generalisability could also be limited by the amount of
missing biochemical and covariate data, as well as the
small fraction of participants who were asked to wear an
accelerometer. However, the key demographics (age,
BMI, sex) of the included sample in this study were
similar to the full 2008 HSE adult cohort.20 Even though
HbA1c is an established clinical measure of glycaemia
that reflects average glucose concentrations over the pre-
vious 2–3 months, it is not a perfect index of blood
glucose for all individuals, and it does not adequately
reflect the glycaemic control status in some diseases that
change the lifespan of erythrocytes, such as chronic liver
disease.21 In addition, although the inclusion of object-
ively measured MVPA is a notable strength, the device
used also has some limitations. Reliance on vertical accel-
erations to quantify movement and lack of waterproofing
means that some activities like cycling may not have been
adequately captured whereas others like swimming were
not captured at all. However, ambulation, which makes
up the vast majority of human movement, is accurately
assessed by accelerometers. Furthermore, cycling and
swimming can be considered to be atypical activities in
this cohort; with only a small proportion of participants
reporting any cycling or swimming activities at all.12
Other studies
Our findings extend previous research using HSE data
which have reported an association between MVPA and
HbA1c in a subsample of older adults.22 The study also
found that neither self-reported or accelerometer
assessed sedentary time was associated with HbA1c.
Others have also reported a lack of association between
sedentary time and HbA1c in HSE using objective and
self-reported data.23 However, previous studies using
HSE did not examine the independent association or
modifying effect of BMI. This contrasts with the strong
and consistent association reported in the present study
for MVPA, suggesting that MVPA may be the stronger
determinant of HbA1c in HSE. Our findings are also
consistent with analyses of National Health and
Nutrition Examination Survey (NHANES) which have
shown that there was no statistical difference in HbA1c
between active obese adults and inactive normal weight
adults, with a further analysis showing that an association
between MVPA and HbA1c was only present in those
with a moderate or high risk of type 2 diabetes;24 25
however, neither of these studies formally tested for an
interaction with BMI. By showing the association of
MVPA with HbA1c is stronger in obese adults, our
results suggest that MVPA may have greater potential to
moderate glycaemic status at higher levels of BMI and
confirms previous research suggesting that active obese
adults have healthier levels of HbA1c than inactive
obese adults. The difference in HbA1c across the mutu-
ally exclusive categories and for every 30 min/day incre-
ment in MVPA observed for obese individuals in our
study is likely to be clinically meaningful beyond dia-
betes risk. For example, in adults without diabetes, each
0.1% unit increment in HbA1c has been associated with
Table 4 Adjusted linear regression model showing the associations between mutually exclusive categories of total accumulated
moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated haemoglobin (HbA1c)
HbA1c (dual
units)
‘Physically active and
non-obese’ ‘Physically active and obese’
‘Physically inactive and
non-obese’
‘Physically
inactive and
obese’Beta (99% CI)* p Value Beta (99% CI) * p Value Beta (99% CI)* p Value
(mmol/mol)
(%)
−3.5 (−5.2 to −1.9)
−0.32 (−0.47 to −0.18)
<0.001 −2.1 (−4.1 to −0.2)
−0.19 (−0.37 to −0.02)
0.005 −1.9 (−3.8 to 0.0)
−0.17 (−0.35 to 0.00)
0.012 Reference
All analyses controlled for primary sampling units, clustering and survey weights.
‘Physically active’ was defined as: ≥150 min/week of total accumulated MVPA.
‘Physically inactive’ was defined as: <150 min/week of total accumulated MVPA.
‘Obese’ was defined as: BMI≥30.0 kg/m2.
‘Non-obese’ was defined as: BMI<30.0 kg/m2.
Bold indicates statistical significance at p<0.01. Model adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer
wear-time.
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) in comparison to the ‘physically inactive and obese’ category.
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a 2% higher risk of mortality and a 4% higher risk of
coronary heart disease or stroke.26
Interpretations
Our finding that MVPA may be metabolically protective
in obese individuals is also consistent with studies that
have shown that cardiorespiratory fitness, which is partly
moderated by MVPA, is also an important determinant
of metabolic health in obesity.11 Other studies have
consistently reported that obese individuals with moder-
ate-to-high fitness have a lower risk of all-cause and car-
diovascular mortality those with normal BMI but low
fitness.27 However, the extent to which MVPA and fitness
can reduce the excess risks of obesity remains controver-
sial,28 supporting the need for further research in this
area. Our results are supported by intervention studies
and known mechanistic pathways linking reduced adipos-
ity and higher physical activity to better glucose control
and reduced insulin resistance.3 29–32 The impact of
physical activity on glucose levels and insulin resistance
in obesity may also be enhanced by preferentially shifting
the storage of excess fat away from metabolically active
sites, such as within visceral compartments or organs,
without effecting overall level adiposity.33
While intervention studies have established and quan-
tified the effects on HbA1c levels following interventions
aimed at increasing physical activity or reducing body
weight in individuals with T2DM,7–9 the associations
between these factors in the general population are less
clear. This is an important limitation as diabetes preven-
tion recommendations and programmes within routine
care are increasingly moving towards identifying and
referring individuals on the basis of HbA1c while also
evaluating effectiveness through changes to HbA1c.4–6
The latter point is particularly important as there is a
lack of data supporting the magnitude of potential dif-
ferences in HbA1c anticipated with specific differences
in health behaviours.
CONCLUSIONS
In conclusion, this study quantifies the association
between MVPA, BMI and HbA1c and shows that the
association of MVPA with HbA1c is stronger in those
with higher BMI levels. Finding ways of translating this
information into encouraging obese people to increase
their physical activity levels as an intervention for lower-
ing HbA1c might be important to improve public health
and allow for more personalised educational and life-
style interventions to be implemented. However, given
the limitations which preclude inferences of causality,
these conclusions need to be confirmed by interrogating
data from completed diabetes prevention trials or
through further experimental studies.
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